Viracept

Viracept is a brand name of nelfinavir, approved by the FDA in the following formulation(s):

VIRACEPT (nelfinavir mesylate - powder; oral)

• 
  Manufacturer: AGOURON
  
  Approval date: March 14, 1997
  
  Strength(s): EQ 50MG BASE/SCOOPFUL ^[RLD]

VIRACEPT (nelfinavir mesylate - tablet; oral)

• 
  Manufacturer: AGOURON
  
  Approval date: March 14, 1997
  
  Strength(s): EQ 250MG BASE ^[RLD]


• 
  Manufacturer: AGOURON
  
  Approval date: April 30, 2003
  
  Strength(s): EQ 625MG BASE ^[RLD]

Has a generic version of Viracept been approved?

No. There is currently no therapeutically equivalent version of Viracept available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viracept. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  HIV protease inhibitors
  Patent 5,484,926
  Issued: January 16, 1996
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried H. & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
  
  
  
  • April 7, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  HIV protease inhibitors
  Patent 5,952,343
  Issued: September 14, 1999
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
  
  
  
  • April 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
  Patent 6,162,812
  Issued: December 19, 2000
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
    ✓ 
    Patent use: TREATMENT OF HIV
  
  
  
  • April 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Viracept Consumer Information (Drugs.com)
• Viracept Consumer Information (Wolters Kluwer)
• Viracept Powder Consumer Information (Wolters Kluwer)
• Viracept Consumer Information (Cerner Multum)
• Viracept Advanced Consumer Information (Micromedex)
• Viracept AHFS DI Monographs (ASHP)
• Nelfinavir Consumer Information (Wolters Kluwer)
• Nelfinavir Powder Consumer Information (Wolters Kluwer)
• Nelfinavir Consumer Information (Cerner Multum)
• Nelfinavir Advanced Consumer Information (Micromedex)
• Nelfinavir Mesylate AHFS DI Monographs (ASHP)